<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889183</url>
  </required_header>
  <id_info>
    <org_study_id>202100166</org_study_id>
    <secondary_id>2021-001247-27</secondary_id>
    <nct_id>NCT04889183</nct_id>
  </id_info>
  <brief_title>SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes</brief_title>
  <acronym>SMART</acronym>
  <official_title>SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide&#xD;
      2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD&#xD;
      progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucagon Like Peptide 1 Receptor Agonist (GLP1-RA) therapies have been introduced as&#xD;
      antidiabetic drugs. In addition, GLP1-RA therapies reduce body weight, in patients with and&#xD;
      without diabetes, without inducing hypoglycemia. Moreover, GLP1-RA reduce albuminuria in&#xD;
      patients with type 2 diabetes, and liraglutide and semaglutide have been shown to improve&#xD;
      various risk markers of CKD progression in non-diabetic obese individuals. It is therefore&#xD;
      likely that these agents delay progression of kidney function decline in high risk&#xD;
      obese/overweight, non-diabetic individuals.&#xD;
&#xD;
      The main objective of the study is to assess the albuminuria lowering effects of semaglutide&#xD;
      2.4 mg s.c. once weekly (Semaglutide 3 mg/ml) compared to placebo in obese/overweight&#xD;
      non-diabetic individuals with elevated albuminuria. This will be tested in a 24-week&#xD;
      randomized placebo controlled double-blind two arm parallel clinical trial with a 4 week&#xD;
      wash-out period after 24 weeks double blind treatment to assess off drug effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo controlled double-blind two arm parallel clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR)</measure>
    <time_frame>Week 1 to week 24</time_frame>
    <description>Measured in first morning void</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Week 1 to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in Iohexol measured glomerular filtration rate (GFR)</measure>
    <time_frame>Week 1 to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary albumin:creatinine ratio (UACR) during wash-out</measure>
    <time_frame>week 24 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate (eGFR) during wash-out</measure>
    <time_frame>week 24 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in body weight</measure>
    <time_frame>Week 1 to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in hip circumference</measure>
    <time_frame>Week 1 to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in systolic and diastolic blood pressure</measure>
    <time_frame>Week 1 to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in extracellular fluid as measured by bio-impedance spectroscopy</measure>
    <time_frame>Week 1 to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in high sensitivity C-reactive protein (CRP)</measure>
    <time_frame>Week 1 to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Obesity</condition>
  <condition>Albuminuria</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with semaglutide 3 mg/ml s.c. once weekly for 24 weeks. The starting dose of semaglutide will be 0.24 mg subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg once weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a matching placebo s.c. once weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.</description>
    <arm_group_label>Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Body Mass index ≥ 27 kg/m2&#xD;
&#xD;
          -  Albuminuria ≥ 30 mg/g and ≤ 3500 mg/g&#xD;
&#xD;
          -  eGFR ≥ 25 ml/min/1.73m2&#xD;
&#xD;
          -  Stable renal function prior to entry into the study defined as no more than 30% eGFR&#xD;
             change in 3 months prior to enrolment&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis with type 1 or type 2 Diabetes&#xD;
&#xD;
          -  Hba1c ≥ 6.5% at screening&#xD;
&#xD;
          -  Cardiovascular disease event in 3 months prior to enrollment&#xD;
&#xD;
          -  Treatment with GLP-1 RA &lt; 4 weeks prior to screening&#xD;
&#xD;
          -  Uncontrolled thyroid disease TSH&gt;6.0 mIU/L or &lt;0.4 mIU/L at screening&#xD;
&#xD;
          -  Acute pancreatitis &lt; 180 days prior to screening&#xD;
&#xD;
          -  History or presence of chronic pancreatitis&#xD;
&#xD;
          -  Females of child-bearing potential who are pregnant, breast-feeding or have intention&#xD;
             of becoming pregnant or are not using adequate contraceptive measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hiddo J. Lambers Heerspink, Prof. dr.</last_name>
    <phone>+31-50-3617859</phone>
    <email>h.j.lambers.heerspink@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Cherney, Prof. dr. MD</last_name>
    <phone>+1-416-340-4151</phone>
    <email>David.Cherney@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>3230</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology University Health Network, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Roland Schmieder, Prof. dr. MD</last_name>
      <email>Roland.Schmieder@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Wuerzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Wanner, Prof. dr. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacobien Verhaave, MD PhD</last_name>
      <email>jverhave@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Femke Waanders, MD PhD</last_name>
      <email>f.waanders@isala.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept Internal Medicine, division of Nephrology Hospital Group Twente</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Andre Van Beek, MD PhD</last_name>
      <email>a.van.beek@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Annemarie Van der Aart, PharmD</last_name>
      <email>a.vd.aart@mzh.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Josep M. Cruzado, MD PhD</last_name>
      <email>jmcruzado@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Da Costa Burela</name>
      <address>
        <city>Lugo</city>
        <zip>27880</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Hiddo Lambers Heerspink</investigator_full_name>
    <investigator_title>Professor at the Department of Clinical Pharmacy and Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

